{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:49:29Z","timestamp":1792705769807,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.seizure.2025.04.017","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T11:55:12Z","timestamp":1746273312000},"page":"32-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Caregiver-reported non-seizure and seizure outcomes with cannabidiol and clobazam in patients aged \u22652 years with Lennox-Gastaut syndrome or Dravet syndrome: A subgroup analysis of the BECOME survey"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1825-846X","authenticated-orcid":false,"given":"M. Scott","family":"Perry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Dixon-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Anne","family":"Meskis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry R.","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy B.","family":"Saurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishan","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne T.","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2025.04.017_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.03177.x","article-title":"Definition and natural history of Lennox-Gastaut syndrome","volume":"52","author":"Camfield","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.04.017_bib0002","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/epi.17241","article-title":"International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on nosology and Definitions","volume":"63","author":"Specchio","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.04.017_bib0003","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/epi.17239","article-title":"ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on nosology and Definitions","volume":"63","author":"Zuberi","year":"2022","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"10.1016\/j.seizure.2025.04.017_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","article-title":"The core Dravet syndrome phenotype","volume":"52","author":"Dravet","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.04.017_bib0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/epi4.13075","article-title":"Refining management strategies for Lennox-Gastaut syndrome: updated algorithms and practical approaches","volume":"10","author":"Auvin","year":"2025","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.seizure.2025.04.017_bib0006","article-title":"Antiseizure medications for Lennox-Gastaut Syndrome: comprehensive review and proposed consensus treatment algorithm","volume":"164","author":"Samanta","year":"2025","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.04.017_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.734612","article-title":"Treatment guidelines for rare, early-onset, treatment-resistant epileptic conditions: a literature review on Dravet syndrome, Lennox-Gastaut syndrome and CDKL5 deficiency disorder","volume":"12","author":"Chin","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.seizure.2025.04.017_bib0008","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40263-020-00784-8","article-title":"Expanding the treatment landscape for Lennox-Gastaut Syndrome: current and future strategies","volume":"35","author":"Strzelczyk","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2025.04.017_bib0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/epi4.12569","article-title":"Guidance on Dravet syndrome from infant to adult care: road map for treatment planning in Europe","volume":"7","author":"Cardenal-Mu\u00f1oz","year":"2022","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.seizure.2025.04.017_bib0010","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/epi.17274","article-title":"International consensus on diagnosis and management of Dravet syndrome","volume":"63","author":"Wirrell","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.04.017_bib0011","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s40265-023-01936-y","article-title":"Pharmacotherapy for Dravet Syndrome: a systematic review and network meta-analysis of randomized controlled trials","volume":"83","author":"Lattanzi","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.seizure.2025.04.017_bib0012","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/epi.17106","article-title":"Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: a time-to-event analysis","volume":"63","author":"Sullivan","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.04.017_bib0013","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2025.04.017_bib0014","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"10125","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2025.04.017_bib0015","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2025.04.017_bib0016","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2025.04.017_bib0017","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/08830738231185241","article-title":"Caregivers\u2019 perspectives on the impact of cannabidiol (CBD) treatment for Dravet and Lennox-Gastaut syndromes: a multinational qualitative study","volume":"38","author":"Marshall","year":"2023","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2025.04.017_bib0018","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/epi4.12319","article-title":"Seizure burden in severe early-life epilepsy: perspectives from parents","volume":"4","author":"Berg","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.seizure.2025.04.017_bib0019","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/epi.16750","article-title":"SCN2A-developmental and epileptic encephalopathies: challenges to trial-readiness for non-seizure outcomes","volume":"62","author":"Berg","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.04.017_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108324","article-title":"Impact of developmental and epileptic encephalopathies on caregivers: a literature review","volume":"124","author":"Gallop","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.04.017_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108978","article-title":"Challenging behavior in children and adolescents with Dravet syndrome: exploring the lived experiences of parents","volume":"138","author":"Postma","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.04.017_bib0022","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/epi.17932","article-title":"A comprehensive systematic literature review of the burden of illness of Lennox\u2013Gastaut syndrome on patients, caregivers, and society","volume":"65","author":"Cross","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.04.017_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2023.107280","article-title":"Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey","volume":"200","author":"Berg","year":"2024","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2025.04.017_bib0024","series-title":"Patient-focused drug development: collecting comprehensive and representative input","year":"2020"},{"key":"10.1016\/j.seizure.2025.04.017_bib0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: expanded access program results","volume":"154","author":"Laux","year":"2019","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2025.04.017_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.673135","article-title":"Results from an Italian expanded access program on cannabidiol treatment in highly refractory Dravet syndrome and Lennox-Gastaut Syndrome","volume":"12","author":"Iannone","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.seizure.2025.04.017_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108958","article-title":"Outcomes from a Spanish expanded access program on cannabidiol treatment in pediatric and adult patients with epilepsy","volume":"137","author":"Villanueva","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.04.017_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109159","article-title":"Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex\u00ae (cannabidiol) in patients with refractory epilepsy","volume":"141","author":"Georgieva","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.04.017_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2024.107300","article-title":"Adherence and discontinuation of prescription cannabidiol for the management of seizure disorders at an integrated care center","volume":"200","author":"Barnes","year":"2024","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2025.04.017_bib0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.seizure.2021.05.014","article-title":"Two-center experience of cannabidiol use in adults with Dravet syndrome","volume":"91","author":"Silvennoinen","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2025.04.017_bib0031","series-title":"ICH reflection paper - proposed ICH guideline work to advance patient focused drug development (PFDD)","year":"2021"},{"key":"10.1016\/j.seizure.2025.04.017_bib0032","series-title":"Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making","year":"2023"},{"key":"10.1016\/j.seizure.2025.04.017_bib0033","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s40263-022-00955-9","article-title":"Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2025.04.017_bib0034","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41687-024-00829-2","article-title":"Development and refinement of the Clinical Global Impression of improvement for non-seizure symptoms measure in Dravet syndrome and Lennox-Gastaut syndrome","volume":"9","author":"Andrews","year":"2025","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.seizure.2025.04.017_bib0035","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13023-023-02626-4","article-title":"The burden of illness in Lennox\u2013Gastaut syndrome: a systematic literature review","volume":"18","author":"Strzelczyk","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.seizure.2025.04.017_bib0036","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/epi4.12998","article-title":"Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox\u2013Gastaut syndrome in clinical practice","volume":"9","author":"Wirrell","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.seizure.2025.04.017_bib0037","series-title":"Change in antiseizure and anxiolytic medications pre- and post-cannabidiol initiation. Presented at American Epilepsy Society Annual Meeting","author":"Morse","year":"2023"},{"key":"10.1016\/j.seizure.2025.04.017_bib0038","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1016\/j.jval.2019.04.1307","article-title":"PND34 Economic burden of probable lennox-gastaut syndrome, probable dravet syndrome, and other refractory epilepsies for United States medicaid health plans","volume":"22","author":"Hollenack","year":"2019","journal-title":"Value in Health"},{"key":"10.1016\/j.seizure.2025.04.017_bib0039","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1016\/j.jval.2019.04.1300","article-title":"PND27 Economic burden of probable lennox-gastaut syndrome, probable dravet syndrome, and other refractory epilepsies for United States commercial health plans","volume":"22","author":"Stockl","year":"2019","journal-title":"Value in Health"},{"key":"10.1016\/j.seizure.2025.04.017_bib0040","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/epi.16546","article-title":"Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis","volume":"61","author":"Lattanzi","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.04.017_bib0041","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/ane.13351","article-title":"Cannabidiol in conjunction with clobazam: analysis of four randomized-controlled trials","volume":"143","author":"Gunning","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2025.04.017_bib0042","doi-asserted-by":"crossref","first-page":"29S","DOI":"10.1177\/1535759720947438","article-title":"SUDEP: advances and challenges","volume":"20","author":"Devinsky","year":"2020","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.seizure.2025.04.017_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108341","article-title":"Expert Opinion: managing sleep disturbances in people with epilepsy","volume":"124","author":"Nobili","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.04.017_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108239","article-title":"The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome","volume":"123","author":"Auvin","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.04.017_bib0045","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.yebeh.2019.03.035","article-title":"Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy","volume":"95","author":"Gaston","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.04.017_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108325","article-title":"Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol","volume":"124","author":"Anderson","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2025.04.017_bib0047","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1111\/epi.13815","article-title":"Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol","volume":"58","author":"Rosenberg","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.04.017_bib0048","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pediatrneurol.2022.10.014","article-title":"Cannabidiol treatment for neurological, cognitive, and psychiatric symptoms in Sturge-Weber Syndrome","volume":"139","author":"Smegal","year":"2023","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2025.04.017_bib0049","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/epi.17000","article-title":"Long-term safety and efficacy of add-on cannabidiol in patients with Lennox\u2013Gastaut syndrome: results of a long-term open-label extension trial","volume":"62","author":"Patel","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2025.04.017_bib0050","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/epi.17036","article-title":"Add-on cannabidiol in patients with Dravet syndrome: results of a long-term open-label extension trial","volume":"62","author":"Scheffer","year":"2021","journal-title":"Epilepsia"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125001074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131125001074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T06:21:25Z","timestamp":1785565285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131125001074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":50,"alternative-id":["S1059131125001074"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2025.04.017","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Caregiver-reported non-seizure and seizure outcomes with cannabidiol and clobazam in patients aged \u22652 years with Lennox-Gastaut syndrome or Dravet syndrome: A subgroup analysis of the BECOME survey","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2025.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}